These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7310392)

  • 21. Prolactin and thyrotropin in serum during electroconvulsive therapy in patients with major depressive illness.
    Apéria B; Thorén M; Wetterberg L
    Acta Psychiatr Scand; 1985 Sep; 72(3):302-8. PubMed ID: 4072731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improvement of Parkinsonism in depressed patients treated with ECT.
    Lebensohn ZM; Jenkins RB
    Am J Psychiatry; 1975 Mar; 132(3):283-5. PubMed ID: 1115272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Serum prolactin response to electroconvulsive therapy in patients with major depression].
    Duan Y
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1991 Oct; 24(5):272-4. PubMed ID: 1752177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: a double-blind study versus placebo.
    Martignoni E; Horowski R; Liuzzi A; Costa A; Dallabonzana D; Cozzi R; Attanasio R; Rainer E; Nappi G
    Clin Neuropharmacol; 1996 Feb; 19(1):72-80. PubMed ID: 8867520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A study of dopaminergic sensitivity in Parkinson's disease: comparison in "de novo" and levodopa-treated patients.
    Llau ME; Durrieu G; Tran MA; Senard JM; Rascol O; Montastruc JL
    Clin Neuropharmacol; 1996 Oct; 19(5):420-7. PubMed ID: 8889285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth hormone and somatomedin serum levels in patients with major depressive illness undergoing electroconvulsive therapy.
    Apéria B; Thorén M; Undén F; Wetterberg L
    Acta Psychiatr Scand; 1986 Jun; 73(6):681-7. PubMed ID: 3751671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Studies on the prolactin response induced by electroconvulsive therapy in schizophrenics.
    Arató M; Erdós A; Kurcz M; Vermes I; Fekete M
    Acta Psychiatr Scand; 1980 Mar; 61(3):239-44. PubMed ID: 7376927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased growth hormone response to apomorphine in Parkinson disease compared with multiple system atrophy.
    Friess E; Kuempfel T; Winkelmann J; Schmid D; Uhr M; Rupprecht R; Holsboer F; Trenkwalder C
    Arch Neurol; 2001 Feb; 58(2):241-6. PubMed ID: 11176962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parkinson's disease, depression, and ECT: a review and case study.
    Asnis G
    Am J Psychiatry; 1977 Feb; 134(2):191-5. PubMed ID: 835744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats.
    Mueller GP; Simpkins J; Meites J; Moore KE
    Neuroendocrinology; 1976; 20(2):121-35. PubMed ID: 958594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diurnal responsiveness to apomorphine.
    Gancher ST; Nutt JG
    Neurology; 1987 Jul; 37(7):1250-3. PubMed ID: 3601094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Electroconvulsive therapy in Parkinson disease. Description of three cases].
    Avila A; Sastre F; Cardona X; Maho P; Bello J; Sancho I
    Neurologia; 1997; 12(7):313-6. PubMed ID: 9432202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms.
    Meltzer HY; Kolakowska T; Fang VS; Fogg L; Robertson A; Lewine R; Strahilevitz M; Busch D
    Arch Gen Psychiatry; 1984 May; 41(5):512-9. PubMed ID: 6721674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma cortisol, PRL, ACTH, AVP and corticotrophin releasing hormone responses to direct current cardioversion and electroconvulsive therapy.
    Florkowski CM; Crozier IG; Nightingale S; Evans MJ; Ellis MJ; Joyce P; Donald RA
    Clin Endocrinol (Oxf); 1996 Feb; 44(2):163-8. PubMed ID: 8849570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease.
    Ueda S; Koyama K; Okubo Y
    J ECT; 2010 Jun; 26(2):111-5. PubMed ID: 20386461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroendocrine study of the mechanism of action of electroconvulsive therapy.
    Arató M; Bagdy G
    Neuropsychobiology; 1982; 8(3):162-8. PubMed ID: 7078718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroendocrine tests during treatment with neuroleptic drugs. III. Plasma growth hormone and prolactin responses to apomorphine.
    Kolakowska T; Gelder M; Fraser S
    Br J Psychiatry; 1981 Nov; 139():408-12. PubMed ID: 6120733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electroconvulsive therapy and the brain: evidence for increased dopamine-mediated responses.
    Costain DW; Cowen PJ; Gelder MG; Grahame-Smith DG
    Lancet; 1982 Aug; 2(8295):400-4. PubMed ID: 6124803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Electric stimulation (ECT) in Parkinson disease].
    Dam H; Pakkenberg H; Bolwig TG
    Ugeskr Laeger; 1992 Jan; 154(4):183-7. PubMed ID: 1736441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The apomorphine test in parkinsonian syndromes.
    D'Costa DF; Abbott RJ; Pye IF; Millac PA
    J Neurol Neurosurg Psychiatry; 1991 Oct; 54(10):870-2. PubMed ID: 1744640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.